Skip to main content
. 2021 Jan 21;43(1):241–254. doi: 10.1080/0886022X.2020.1871012

Table 2.

Summary of patient characteristics and outcomes in studies reporting frequency of HK in HD patients stratified by population.

HD population
(no. of studies)
Publication type Study design Cohort size (N) Age (years)a, % male HD vintage (months)a,b Median prevalence (IQR) Incidence rate
ESRD (n = 40)
[9,17,20–23,25,26,29–31, 35–41,43,44,46,47, 50,54,55,59,63, 65–67,70,72,74–79, 82,84,85]
33 Full texts
7 Abstracts
22 Observational
3 non-RCT trials
12 RCTs
3 NR
10–55,183 60.6 (5.3), 59% 42.3 (27.9)
3x weekly schedule
19.0%
(7.8–38.9%)
15.1–26.0 events per 100 patient-months
CKD (n = 21)
[18,19,24,27,32–34, 42,45,48,49, 51,53,56–58,60,61, 64,69,71]
17 Full texts
4 Abstracts
14 Observational
2 non-RCT trials
3 RCTs
2 NR
5–74,219 56.3 (6.9), 58.8% 59.8 (20.1)
3x weekly schedule
24.0%
(7.6–38.8%)
AKI (n = 4)
[28,52,73,80]
2 Full texts
2 Abstracts
All observational 46–105 52.8 (14.7), 63.8% Intermittent HD 27.3%
(16.0–38.4%)
eHD (n = 5)
[16,62,68,81,83]
3 Full text
2 Abstract
4 Observational
1 NR
37–489 53.8 (7.5), 60.2% eHD 24.0%
(21.1–37.6%)

AKI: acute kidney injury; CKD: chronic kidney disease; eHD: emergency hemodialysis; ESRD: end-stage renal disease; HD: hemodialysis; IQR: interquartile range; NR: not reported; RCTs: randomized controlled trials.

aMean (SD).

bReported in a limited number of studies only.